Get the Stockscreener App
6.08
1.78%
-0.11
Verastem Inc stock is traded at $6.08, with a volume of 2.02M.
It is down -1.78% in the last 24 hours and up +41.72% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$6.19
Open:
$6
24h Volume:
2.02M
Relative Volume:
0.86
Market Cap:
$334.09M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-1.4793
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
-0.98%
1M Performance:
+41.72%
6M Performance:
+0.00%
1Y Performance:
+150.21%
1-Day Range:
$5.8801
$6.33
1-Week Range:
$5.775
$6.78
52-Week Range:
$2.10
$9.10
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
6.08 | 339.04M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
How strong is Verastem Inc. company’s balance sheetPost Market Planner That Work - jammulinksnews.com
Why Verastem Inc. stock attracts strong analyst attentionBuy Signal Based on Chart Analysis Confirmed - beatles.ru
When is Verastem Inc. stock expected to show significant growthSwing Trade Updates For Consistent Profits - jammulinksnews.com
How does Verastem Inc. compare to its industry peersBreakout Stocks Tracker With High Returns - jammulinksnews.com
What institutional investors are buying Verastem Inc. stockPost Market Planner For Smart Trading - jammulinksnews.com
What catalysts could drive Verastem Inc. stock higher in 2025Market Forecast Tips With Proven Results - jammulinksnews.com
Verastem’s Phase 3 Study: A New Hope for Ovarian Cancer Treatment - TipRanks
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline - Yahoo Finance
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - Yahoo.co
Short Term Trend Reversal in Verastem Inc. PossibleTop Gaining Picks With Entry Signals Identified - metal.it
What are Verastem Inc. company’s key revenue driversFree Stock Trend Scanner With Proven Results - jammulinksnews.com
Is Verastem Inc. a growth stock or a value stockSwing Trade Forecasts For Smart Trading - jammulinksnews.com
How does Verastem Inc. generate profit in a changing economyBreakout Stocks Picks That Work - jammulinksnews.com
What is the dividend policy of Verastem Inc. stockCapitalize on market shifts before others do - jammulinksnews.com
Is it the right time to buy Verastem Inc. stockDiscover high-impact stocks for growth - jammulinksnews.com
Is Verastem Inc. stock overvalued or undervaluedExplosive capital appreciation - jammulinksnews.com
What drives Verastem Inc. stock priceUnstoppable profit momentum - PrintWeekIndia
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Pancreatic Cancer - Targeted Oncology
Verastem Inc. Stock Analysis and ForecastRapid capital growth - PrintWeekIndia
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer - BioSpace
What analysts say about Verastem Inc. stockFree Market Dynamics Reports - Autocar Professional
Is Verastem Inc. a good long term investmentAccelerated earnings growth - Autocar Professional
Verastem’s Phase 3 Study Update: A Potential Game-Changer in Ovarian Cancer Treatment - TipRanks
Verastem's Fast-Track KRAS G12D Inhibitor: A Strategic Play in a High-Unmet-Need Oncology Market - AInvest
Verastem Oncology gets FDA fast track status for cancer drug - Seeking Alpha
Verastem Oncology’s VS-7375 Granted Fast Track Designation by the FDA - Contract Pharma
FDA grants fast track designation to Verastem’s pancreatic cancer drug By Investing.com - Investing.com Canada
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
(VSTM) Proactive Strategies - news.stocktradersdaily.com
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):